Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Rene de Waal-Malefyt"'
Autor:
Akiko Hashimoto-Tane, Edward P. Bowman, Machie Sakuma, Natsumi Yoneda, Katsuyuki Yugi, Rene de Waal Malefyt, Takashi Saito
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Lymphocyte activation gene (Lag)-3 is an inhibitory co-receptor and target of immune checkpoint inhibitor (ICI) therapy for cancer. The dynamic behavior of Lag-3 was analyzed at the immune synapse upon T-cell activation to elucidate the Lag-3 inhibit
Externí odkaz:
https://doaj.org/article/01488bb5ac8c4a6ab38ab7b584d9ff15
Autor:
Martin Oft, Michael Totagrande, Luis Zuniga, David B Rosen, Priyanka Balasubrahmanyam, Zhenya Koliesnik, Ryan Burgess, Kim Q Tran, Michele Bauer, Bharghavi Jayaraman, Cindy Buffone, Jan Emmerich, Deepti Chaturvedi, Deepti Rokkam, Rene De Waal Malefyt, Heiko Greb, Navneet Ratti, Sandro Vivona, Robert Kastelein, Patrick Lupardus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3e0b02efc0da4cb49b22cd8ab1e23832
Autor:
Sukanya Raghavan, Nataliya Tovbis-Shifrin, Christina Kochel, Anandi Sawant, Marielle Mello, Manjiri Sathe, Wendy Blumenschein, Eric S. Muise, Alissa Chackerian, Elaine M. Pinheiro, Thomas W. Rosahl, Hervé Luche, Rene de Waal Malefyt
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Programmed cell death-1 (PD-1) blockade has a profound effect on the ability of the immune system to eliminate tumors, but many questions remain about the cell types involved and the underlying mechanisms of immune activation. To shed some light on t
Externí odkaz:
https://doaj.org/article/72fd7ab5d05749e780b38e08a7d4a277
Autor:
Joseph A. Perry, Lindsey Shallberg, Joseph T. Clark, Jodi A. Gullicksrud, Jonathan H. DeLong, Bonnie B. Douglas, Andrew P. Hart, Zachary Lanzar, Keenan O’Dea, Christoph Konradt, Jeongho Park, Juhi R. Kuchroo, Daniel Grubaugh, Arielle Glatman Zaretsky, Igor E. Brodsky, Rene de Waal Malefyt, David A. Christian, Arlene H. Sharpe, Christopher A. Hunter
Publikováno v:
Nature Immunology. 23:743-756
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1360105b00b4e769847c9bcbc34f3710
https://doi.org/10.1038/s41590-022-01170-w
https://doi.org/10.1038/s41590-022-01170-w
Publikováno v:
ImmunoHorizons. 5:384-394
Resistance to the parasite Toxoplasma gondii is mediated by NK and T cell production of IFN-γ, but the failure to contract this response can lead to severe T cell–dependent immunopathology. Although the cytokines IL-10 and IL-27 prevent immune hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96ebbeea7f687104ed3eedbdf2d15d2b
https://doi.org/10.4049/immunohorizons.2100007
https://doi.org/10.4049/immunohorizons.2100007
Publikováno v:
International Immunopharmacology. 119:109566
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9fc256912f8f0783f319fa157590fba
https://doi.org/10.1016/j.intimp.2022.109566
https://doi.org/10.1016/j.intimp.2022.109566
Autor:
Martin Oft, Navneet Ratti, Sandro Vivona, Jan Emmerich, Romina Riener, Ievgen O. Koliesnik, Scott McCauley, Michele Bauer, Marie Semana, Deepti Rokkam, Bhargavi Jayaraman, Rene de Waal Malefyt, Paul-Joseph Aspuria, Michael Totagrande, Anita Mehta-Damani, Patrick J. Lupardus, Rob A. Kastelein
Publikováno v:
Cancer Research. 83:1801-1801
High-dose Interleukin-2 (IL-2) monotherapy induces complete responses in cancer patients but its use is limited by acute vascular toxicities including capillary leak syndrome and severe hypotension 1,2. IL-2 activates lymphocytes and NK-cells through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43a4b8e656e3c87b806bcec92def646
https://doi.org/10.1158/1538-7445.am2023-1801
https://doi.org/10.1158/1538-7445.am2023-1801
Abstract 1833: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity
Autor:
Ievgen Koliesnik, Jan Emmerich, Kim Q. Tran, Michele Bauer, Michael Totagrande, Bhargavi Jayaraman, Cindy Buffone, Priyanka Balasubrahmanyam, Deepti Rokkam, Rene de Waal Malefyt, Luis Zuniga, Heiko Greb, Navneet Ratti, Sandro Vivona, Martin Oft, Patrick J. Lupardus, Robert A. Kastelein
Publikováno v:
Cancer Research. 83:1833-1833
Here we report on a novel human IL-12 partial agonist (hIL-12v) that has diminished binding to IL-12Rb1. IL-12v is designed to more selectively engage antigen activated T-cells, which strongly upregulate IL-12Rb1 upon activation, and to reduce stimul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43b30cab5d0df1c8a2e56d783686ec2d
https://doi.org/10.1158/1538-7445.am2023-1833
https://doi.org/10.1158/1538-7445.am2023-1833
Autor:
Laurence Fayadat-Dilman, Christine Andrews, Gulesi Ayanoglu, Liming Liu, Robert A. Kastelein, Aarron T. Willingham, Sabine Le Saux, Svetlana Sadekova, Dan Malashock, Hans van Eenennaam, Sophie Li, Ying Yu, Soonmo Peter Kang, Beth Hutchins, Andrea van Elsas, John Dulos, Rene De Waal Malefyt, Julie Lee, Frederique M. Poulet, Gregory J. Carven, Constance Cullen, Gary C. Starling, Mark Hsieh, Danuta J. Herzyk, Michel Streuli, Mark A. McCoy, George Soder
Publikováno v:
Molecular Cancer Therapeutics. 19:1298-1307
The programmed cell death 1 (PD-1) pathway represents a major immune checkpoint, which may be engaged by cells in the tumor microenvironment to overcome active T-cell immune surveillance. Pembrolizumab (Keytruda®, MK-3475) is a potent and highly sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44ee4cad68943c640dee7d7ddd1ef5be
https://doi.org/10.1158/1535-7163.mct-19-0774
https://doi.org/10.1158/1535-7163.mct-19-0774
Autor:
Ben Nicholas, Jane Guo, Hyun‐Hee Lee, Alistair Bailey, Rene de Waal Malefyt, Milenko Cicmil, Ratko Djukanovic
Asthma is a disease of complex origin and multiple pathologies. There are currently very few biomarkers of proven utility in its diagnosis, management or response to treatment. Recent studies have identified multiple asthma phenotypes following biofl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3246b6669865a593b04184854f476f
https://doi.org/10.1101/2022.01.12.22268892
https://doi.org/10.1101/2022.01.12.22268892
